Lexeo Therapeutics, Inc. Operating Lease, Expense
Lexeo Therapeutics, Inc. (LXEO) reported Operating Lease, Expense of $665.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-12
- Lexeo Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $665.00K, a 0.30% increase year-over-year.
- Lexeo Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $668.00K, a 0.75% increase year-over-year.
- Lexeo Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $667.00K, a 2.46% increase year-over-year.
- Lexeo Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $667.00K, a 2.14% increase year-over-year.
- Lexeo Therapeutics, Inc. operating lease, expense for fiscal 2025 was $2.65M, a 1.69% increase from fiscal 2024.
- Lexeo Therapeutics, Inc. operating lease, expense for fiscal 2024 was $2.61M, a 4.16% increase from fiscal 2023.
- Lexeo Therapeutics, Inc. operating lease, expense for fiscal 2023 was $2.50M, a 39.39% increase from fiscal 2022.
- Lexeo Therapeutics, Inc. operating lease, expense for fiscal 2022 was $1.79M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $665.00K 10-Q · filed 2026-08-12 | $1.33M 10-Q · filed 2026-08-12 | $2.00M derived: sum of 3 quarters · filed 2026-08-12 | $2.67M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $668.00K 10-Q · filed 2026-05-11 | $1.33M derived: sum of 2 quarters · filed 2026-05-11 | $2.00M derived: sum of 3 quarters · filed 2026-05-11 | $2.67M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | $667.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.33M derived: sum of 2 quarters · filed 2026-03-30 | $2.00M derived: sum of 3 quarters · filed 2026-08-12 | $2.65M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $667.00K 10-Q · filed 2025-11-05 | $1.33M derived: sum of 2 quarters · filed 2026-08-12 | $1.98M 10-Q · filed 2025-11-05 | $2.64M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | $663.00K 10-Q · filed 2026-08-12 | $659.00K 10-Q · filed 2025-08-14 | $1.33M 10-Q · filed 2026-08-12 | $1.32M 10-Q · filed 2025-08-14 | $1.98M derived: sum of 3 quarters · filed 2026-08-12 | $2.63M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $663.00K 10-Q · filed 2026-05-11 | $1.31M derived: sum of 2 quarters · filed 2026-05-11 | $1.97M derived: sum of 3 quarters · filed 2026-05-11 | $2.62M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | $651.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.30M derived: sum of 2 quarters · filed 2026-03-30 | $1.96M derived: sum of 3 quarters · filed 2026-03-30 | $2.61M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $653.00K 10-Q · filed 2025-11-05 | $1.30M derived: sum of 2 quarters · filed 2025-11-05 | $1.96M 10-Q · filed 2025-11-05 | $2.36M derived: sum of 4 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $652.00K 10-Q · filed 2025-08-14 | $1.30M 10-Q · filed 2025-08-14 | $1.70M derived: sum of 3 quarters · filed 2025-08-14 | $2.54M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $650.00K 10-Q · filed 2025-05-12 | $1.05M derived: sum of 2 quarters · filed 2025-05-12 | $1.88M derived: sum of 3 quarters · filed 2025-05-12 | $2.55M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.23M derived: sum of 2 quarters · filed 2025-03-24 | $1.90M derived: sum of 3 quarters · filed 2025-03-24 | $2.50M 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $832.00K 10-Q · filed 2024-11-13 | $615.00K 10-Q · filed 2023-12-11 | $1.49M derived: sum of 2 quarters · filed 2024-11-13 | $2.10M 10-Q · filed 2024-11-13 | $1.84M 10-Q · filed 2023-12-11 | $2.68M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $662.00K 10-Q · filed 2024-08-12 | $1.27M 10-Q · filed 2024-08-12 | $1.85M derived: sum of 3 quarters · filed 2024-08-12 | $2.46M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | $606.00K 10-Q · filed 2024-05-09 | $1.19M derived: sum of 2 quarters · filed 2024-05-09 | $1.79M derived: sum of 3 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $1.19M derived: sum of 2 quarters · filed 2024-03-11 | $1.79M 10-K · filed 2024-03-11 | ||||
| 2022-09-30 | $606.00K 10-Q · filed 2023-12-11 | $1.21M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |